ArticleCancer immunology, immunotherapy : CII2023

CD24 is a novel target of chimeric antigen receptor T cells for the treatment of triple negative breast cancer.

Peiwei Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.